Literature DB >> 20883724

Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.

Francisco M Codoñer1, Christian Pou, Alexander Thielen, Federico García, Rafael Delgado, David Dalmau, José Ramon Santos, Maria José Buzón, Javier Martínez-Picado, Miguel Alvarez-Tejado, Bonaventura Clotet, Lidia Ruiz, Roger Paredes.   

Abstract

Using quantitative deep HIV-1 sequencing in a subject who developed virological failure to deep salvage therapy with raltegravir, we found that most Q148R and N155H mutants detected at the time of virological failure originated from pre-existing minority Q148R and N155H variants through independent evolutionary clusters. Double 148R+N155H mutants were also detected in 1.7% of viruses at virological failure in association with E138K and/or G163R. Our findings illustrate the ability of HIV-1 to escape from suboptimal antiretroviral drug pressure through selection of pre-existing drug-resistant mutants, underscoring the importance of using fully active antiretroviral regimens to treat all HIV-1-infected subjects.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20883724     DOI: 10.1016/j.antiviral.2010.09.016

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  20 in total

1.  Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

Authors:  Daniele Armenia; Ina Vandenbroucke; Lavinia Fabeni; Herwig Van Marck; Valeria Cento; Roberta D'Arrigo; Liesbeth Van Wesenbeeck; Fernanda Scopelliti; Valeria Micheli; Bianca Bruzzone; Sergio Lo Caputo; Jeroen Aerssens; Giuliano Rizzardini; Valerio Tozzi; Pasquale Narciso; Andrea Antinori; Lieven Stuyver; Carlo Federico Perno; Francesca Ceccherini-Silberstein
Journal:  J Infect Dis       Date:  2012-01-11       Impact factor: 5.226

2.  Switching between raltegravir resistance pathways analyzed by deep sequencing.

Authors:  Rithun Mukherjee; Shane T Jensen; Frances Male; Kyle Bittinger; Richard L Hodinka; Michael D Miller; Frederic D Bushman
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

3.  Efficacy of raltegravir, etravirine and darunavir/ritonavir for treatment-experienced HIV patients from a non-urban clinic population in the United States.

Authors:  Andrew M Ebers; Yusra Alkabab; Brian Wispelwey; Rebecca Dillingham; Xin-Qun Wang; Julie Schexnayder; Scott K Heysell
Journal:  Ther Adv Infect Dis       Date:  2017-07-13

4.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

5.  Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

Authors:  Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Michael J Kozal; Evguenia S Svarovskaia; Jeffrey A Johnson; Anna Maria Geretti; Karin J Metzner; Martin R Jakobsen; Katherine Huppler Hullsiek; Lars Ostergaard; Michael D Miller; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2012-12-21       Impact factor: 5.226

Review 6.  The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.

Authors:  Natalia Stella-Ascariz; José Ramón Arribas; Roger Paredes; Jonathan Z Li
Journal:  J Infect Dis       Date:  2017-12-01       Impact factor: 5.226

7.  HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe.

Authors:  Amanda Madyadi; Milcah Dhoro; Tinei Shamu; Tendai Washaya; Vinie Kouamou; Benjamin Chimukangara; David Katzenstein; Justen Manasa
Journal:  AIDS Res Hum Retroviruses       Date:  2021-12       Impact factor: 2.205

8.  Clinical implications of HIV-1 minority variants.

Authors:  Jonathan Z Li; Daniel R Kuritzkes
Journal:  Clin Infect Dis       Date:  2013-02-27       Impact factor: 9.079

9.  Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations.

Authors:  Mark A Winters; Robert M Lloyd; Robert W Shafer; Michael J Kozal; Michael D Miller; Mark Holodniy
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

10.  Prolonged and substantial discordance in prevalence of raltegravir-resistant HIV-1 in plasma versus PBMC samples revealed by 454 "deep" sequencing.

Authors:  Guinevere Q Lee; Luke C Swenson; Art F Y Poon; Jeffrey N Martin; Hiroyu Hatano; Steven G Deeks; P Richard Harrigan
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.